Skip to main content
. Author manuscript; available in PMC: 2018 Dec 1.
Published in final edited form as: Arch Pathol Lab Med. 2017 Aug 22;141(12):1697–1704. doi: 10.5858/arpa.2016-0580-OA

Figure 3.

Figure 3.

CD155 expression (exp.) levels do not correlate with susceptibility to, propagation of, and cancer cell killing by polio-rhinovirus recombinant (PVSRIPO). A, CD155 immunoblot of lysates from a panel of transduced TRAMP-C2 lines; quantitation of immunoblot signal is shown below. B, Standard fluorescence-activated cell sorter (FACS)/quantitative FACS (qFACS) analyses of CD155 in TRAMP-C2 clones 1, 2, 5, 6; lane numbers corresponding to A are shown. Numbers atop the orange peaks represent CD155 receptors per cell as determined by qFACS (see Materials and Methods); receptor numbers in clone 6 were outside the linear range and could not be evaluated (N.D.). C, TRAMP-C2 clone 1, 5, and 6 cultures were infected with polio-rhinovirus recombinant (PVSRIPO) (multiplicity of infection [MOI] = 1) and lysed at the indicated intervals, and plaque-forming units (pfu) per cell were determined by standard plaque assay. The bottom panel indicates the approximate percentage of cells exhibiting cytopathogenic effects in cultures at the corresponding intervals after infection. Abbreviation: hpi, hours postinfection.